Top Markets
#1 Bedrock Bedrock +50.85%
#2 pippin pippin +21.68%
#3 IQ IQ +20.70%
#4 Naoris Protocol Naoris Protocol +17.39%
#5 Irys Irys +16.18%
#6 Magma Finance Magma Finance +15.58%
#7 ETHGas ETHGas +15.36%
#8 Aria.AI Aria.AI +15.19%
#9 パンチ (Punch) パンチ (Punch) +14.59%
#10 Bitway Bitway +12.30%
Coin of the day
Bedrock Bedrock
Instellingen
Taal
DUTCH
Valuta
USD
Thema
Fusion Antibodies plc Fusion Antibodies plc

Fusion Antibodies plc

FAB
Rang in aandelen #20442
Fusion Antibodies plc, a contract research organization, engages in the... Fusion Antibodies plc, a contract research organization, engages in the research, development, and manufacture of recombinant proteins and antibodies primarily for cancer and infectious diseases in the United Kingdom, the rest of Europe, North America, and internationally. It offers monoclonal antibody discovery and development, antibody sequencing, antibody engineering, antibody humanization and rational affinity maturation platform, recombinant protein expression, and stable cell line development and cGMP scale up services. The company serves pharmaceutical, biotech, and diagnostic companies. It has a collaboration partnership with Celonic AG. Fusion Antibodies plc was incorporated in 2000 and is headquartered in Belfast, the United Kingdom.
Aandeelprijs
$0.16328419
Marktkapitalisatie
$204.14K
Verandering (1 dag)
4.35%
Verandering (1 jaar)
102.45%
Land
GB
Handel Fusion Antibodies plc (FAB)

Categorie

Healthcare
P/B-ratio voor Fusion Antibodies plc (FAB)
P/B-ratio op March 2026 TTM: 19.49
Volgens de meest recente financiële rapporten en aandelenkoers van Fusion Antibodies plc is de huidige P/B-ratio (TTM) 19.49. Eind 2024 had het bedrijf een P/B-ratio van 1.19.
P/B-ratiohistoriek voor Fusion Antibodies plc van 2013 tot 2026
P/B-ratio aan het einde van elk jaar
Jaar P/B-ratio Wijzigen
2026 (TTM) 19.49 121.25%
2025 8.81 638.88%
2024 1.19 -86.62%
2023 8.92 111.06%
2022 4.23 -49.81%
2021 8.42 93.06%
2020 4.36 270.89%
2019 1.18 -54.53%
2018 2.59 -83.83%
2017 15.99 -14.59%
2016 18.73 -88.38%
2015 161.16 -102.17%
2014 -7.41K -918.70%
2013 905.56 0.00%
P/B-ratio voor vergelijkbare bedrijven of concurrenten
Bedrijf P/B-ratio Verschil in P/B-ratio Land
Novo Nordisk A/S Novo Nordisk A/S
Novo Nordisk A/S
NVO.US
 5.6573 -70.98%
DK
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 6.3842 -67.25%
US
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
REGN.US
 2.4551 -87.40%
US
UCB SA UCB SA
UCB SA
UCB.BR
 4.364 -77.61%
BE
Argenx SE Argenx SE
Argenx SE
ARGX.US
 5.9034 -69.71%
NL